MICHAEL FRUMOVITZ to Neoplasm Recurrence, Local
This is a "connection" page, showing publications MICHAEL FRUMOVITZ has written about Neoplasm Recurrence, Local.
Connection Strength
1.548
-
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575.
Score: 0.197
-
Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstet Gynecol. 2019 12; 134(6):1253-1259.
Score: 0.190
-
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017 Jan; 144(1):46-50.
Score: 0.154
-
Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016 Dec; 143(3):552-557.
Score: 0.152
-
Rhabdomyosarcoma of the cervix in adult women and younger patients. Gynecol Oncol. 2012 Sep; 126(3):351-6.
Score: 0.113
-
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
Score: 0.063
-
Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecol Oncol. 2004 Jan; 92(1):205-10.
Score: 0.063
-
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623.
Score: 0.061
-
The role of postoperative radiation after radical hysterectomy for women with early-stage neuroendocrine carcinoma of the cervix: A meta-analysis. Gynecol Oncol. 2023 03; 170:328-332.
Score: 0.059
-
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. Am J Obstet Gynecol. 2023 04; 228(4):445.e1-445.e8.
Score: 0.059
-
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489.
Score: 0.058
-
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020 06; 21(6):851-860.
Score: 0.049
-
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166.
Score: 0.048
-
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019 06; 153(3):541-548.
Score: 0.046
-
Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44.
Score: 0.036
-
Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Int J Gynecol Cancer. 2015 Sep; 25(7):1292-9.
Score: 0.035
-
Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec; 116(6):1358-1365.
Score: 0.026
-
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol. 2024 Dec; 191:143-149.
Score: 0.017
-
Impact of pelvic radiation therapy in patients with early neuroendocrine cervical carcinoma and no residual disease in the radical hysterectomy specimen: a NeCTuR study. Int J Gynecol Cancer. 2024 Feb 05; 34(2):209-215.
Score: 0.016
-
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study. Int J Gynecol Cancer. 2023 02 06; 33(2):293-298.
Score: 0.015
-
Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer. Radiother Oncol. 2019 06; 135:58-64.
Score: 0.011
-
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018 Nov 15; 379(20):1895-1904.
Score: 0.011
-
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018; 9:2102.
Score: 0.011
-
Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecol Oncol. 2018 03; 148(3):474-479.
Score: 0.010
-
Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):546-553.
Score: 0.010
-
Is it equivalent? Evaluation of the clinical activity of single agent Lipodox? compared to single agent Doxil? in ovarian cancer treatment. J Oncol Pharm Pract. 2016 Aug; 22(4):599-604.
Score: 0.009
-
Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery. Gynecol Oncol. 2015 Sep; 138(3):585-9.
Score: 0.009
-
Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system? Gynecol Oncol. 2015 Feb; 136(2):269-73.
Score: 0.008
-
The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol. 2012 May; 125(2):336-42.
Score: 0.007
-
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol. 2007 Dec; 107(3):458-63.
Score: 0.005